Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2022-08-30 00:00:00 ET · period of report 2022-08-29 · accession 0000899243-22-030087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-30 | 2022-08-29 | SPRO | Shukla Sath | CFO | S - Sale | $0.89 | -6,017 | 56.1K | -10% | -$5,355 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-29 | S | D | 6,017 | $0.89 | 56,064 | D | — | — | (F2) Represents the weighted average sales price per share. The shares sold at prices ranging from $0.8839 to $0.9002 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. (F3) Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. 18,050 of the RSUs vest in three equal annual installments beginning on August 26, 2023 and 38,014 of the RSUs vest in four equal annual installments beginning on February 1, 2023, in each case subject to the Reporting Person's continued service through the applicable vesting date. |